# Country-Specific Template Fix - Implementation Complete ✅

## Summary

Fixed template generation to be **country-specific** per user request. Templates now show actual regulatory authority names (Pharmacy and Poisons Board, NACOSTI) instead of generic terms (IND/CTA, Ministerial Approval).

---

## User Feedback Addressed

**User said:**
> "Kenya is regulated by Pharmacy and Poisons Board (PPB), NACOSTI - why is there no specific mention of them in the task template? These templates must be as specific as possible."

> "I'm not sure what you are referring to in 'IND/CTA Submission and Review - Kenya'"

> "Please remove the country from 'NLM Submission for ClinicalTrials.gov (NCT# assigned)'"

> "What is 'Ministerial/Final Approval'?"

**All issues have been FIXED ✅**

---

## Before & After Comparison

### Before (Generic):

```
Kenya Phase III Template - Regulatory Tasks:
  ❌ IND/CTA Submission & Review - Kenya
  ❌ Ministerial/Final Approval - Kenya
  ❌ IND Submission to FDA (if applicable) - Kenya
  ❌ NLM Submission for ClinicalTrials.gov (NCT# assigned) - Kenya
  ❌ IRB Continuing Review - Kenya
  ❌ Regulatory Affairs Submits Final CSR to FDA - Kenya
  ✅ Institutional Ethics Committee (EC) Approval - Kenya
  ✅ Pharmacy and Poisons Board Approval - Kenya
  ✅ National Commission for Science, Technology and Innovation Clearance - Kenya
```

**Problems:**
- Generic US terms (IND/CTA, FDA) appearing in Kenya template
- Country suffix on generic tasks
- No filtering for country-specific applicability

### After (Country-Specific):

```
Kenya Phase III Template - Regulatory Tasks:
  ✅ Institutional Ethics Committee (EC) Approval - Kenya
  ✅ Pharmacy and Poisons Board Approval - Kenya
  ✅ National Commission for Science, Technology and Innovation Clearance - Kenya
  ✅ ClinicalTrials.gov Registration (NCT#)
  ✅ IRB/EC Continuing Review
  ✅ Final CSR Submission to Regulatory Authority
  ✅ Protocol Amendment Submission & Approval
  ✅ Annual Safety Report
  (and other generic regulatory tasks - no country suffix)
```

**Improvements:**
- Kenya-specific 3-layer regulatory workflow clearly identified
- No US-specific tasks (IND/CTA, FDA submissions)
- Generic tasks have generic names (not country-specific)
- Accurate representation of Kenya's regulatory structure per Regulatory Authorities.txt

---

## Changes Implemented

### 1. Removed Country Suffix from Generic Tasks

**Before:**
```python
name=f"{task_def['name']} - {workflow['country_name']}"  # ALL tasks got country suffix
```

**After:**
```python
name=task_def['name']  # Use task name as-is from ontology
```

**Result:** Only country-specific workflow tasks (REG-KE-EC, REG-KE-REG, REG-KE-NACOSTI) have "- Kenya" suffix.

### 2. Added Country-Specific Task Filtering

**New Logic:**
```python
# Skip US-only tasks for non-US countries
us_only_tasks = ['REG-001', 'REG-011']  # IND/CTA and IND Submission
if country_code != 'US' and task_id in us_only_tasks:
    continue

# Check applicable_countries field in ontology
applicable_countries = task_def.get('applicable_countries', [])
if applicable_countries and country_code not in applicable_countries:
    continue

# Skip generic "Ministerial/Final Approval" for countries with specific workflows
if task_id == 'REG-INT-003' and workflow_type in ['three_layer_sequential', 'four_layer_sequential']:
    continue
```

**Result:** Kenya templates no longer show IND/CTA, FDA submissions, or generic ministerial approval.

### 3. Renamed Generic Tasks

| Old Name (US-Centric) | New Name (Generic) |
|-----------------------|-------------------|
| "NLM Submission for ClinicalTrials.gov (NCT# assigned)" | "ClinicalTrials.gov Registration (NCT#)" |
| "IRB Continuing Review" | "IRB/EC Continuing Review" |
| "Regulatory Affairs Submits Final CSR to FDA" | "Final CSR Submission to Regulatory Authority" |

### 4. Added applicable_countries Field

Updated task ontology to support country-specific filtering:
```yaml
  - id: REG-011
    name: "IND Submission to FDA (if applicable)"
    applicable_countries: ["US"]  # Only appears in US templates
```

---

## Kenya's Three-Layer Regulatory Workflow

Based on **Regulatory Authorities.txt** (lines 16234-16266):

### Layer 1: Ethics Committee (EC)
- **Authority**: Institutional Ethics Committee accredited by NACOSTI
- **Review Time**: Variable (depends on institutional EC)
- **Purpose**: Ethical approval for patient protection
- **Requirement**: MUST be obtained BEFORE PPB submission (sequential, not parallel)

### Layer 2: Pharmacy and Poisons Board (PPB)
- **Authority**: Kenya's primary drug regulatory authority
- **Review Time**: 30 working days
- **Purpose**: Drug safety, efficacy, quality assessment
- **Requirement**: Review conducted by Expert Committee on Clinical Trials (ECCT)

### Layer 3: National Commission for Science, Technology and Innovation (NACOSTI)
- **Authority**: Research oversight and licensing
- **Review Time**: ~30 days
- **Purpose**: Research license for all clinical research in Kenya
- **Requirement**: Must be obtained before study initiation
- **Validity**: 1 year (renewable with progress report)

### Total Timeline
- **Sequential**: EC approval (variable) → PPB approval (30 days) → NACOSTI license (30 days)
- **Minimum**: ~60-90 days for all regulatory approvals

**Key Regulatory Quotes from Source:**
> "Clinical research in Kenya is regulated and overseen by the Pharmacy and Poisons Board (PPB) and the National Commission for Science, Technology and Innovation (NACOSTI)." (Line 16234)

> "The PPB review and approval process may not be conducted in parallel with the ethics committee (EC) review. Rather, EC approval must be obtained prior to applying for PPB approval." (Lines 16301-16302)

---

## Testing Results

### Kenya Phase III Infectious Disease

```
Total Tasks: 100
Total Dependencies: 22
Total Regulatory Tasks: 24

Kenya-Specific (3-Layer):
  1. Institutional Ethics Committee (EC) Approval - Kenya
  2. Pharmacy and Poisons Board Approval - Kenya
  3. National Commission for Science, Technology and Innovation Clearance - Kenya

Generic Tasks (No Country Suffix):
  - ClinicalTrials.gov Registration (NCT#)
  - IRB/EC Continuing Review
  - Final CSR Submission to Regulatory Authority
  - Protocol Amendment Submission & Approval
  - Annual Safety Report
  - Preparation of Draft CSR (including TFLs)
  - (18 more generic regulatory tasks)

Removed Tasks:
  ❌ IND/CTA Submission & Review (US-specific)
  ❌ IND Submission to FDA (US-specific)
  ❌ Ministerial/Final Approval (Kenya has 3-layer instead)
```

### US Phase III Oncology (For Comparison)

```
US-Specific:
  1. IND/CTA Submission & Review (appears in US, not Kenya) ✅
  2. IND Submission to FDA (if applicable) (appears in US, not Kenya) ✅

Generic Tasks:
  - Same generic tasks as Kenya
  - Same non-country-specific names
```

---

## Files Modified

### Backend Files:

1. **`backend/services/template_generator.py`**
   - Removed country suffix from generic task names (line 147)
   - Added country-specific task filtering
   - Added US-only task exclusions for non-US countries
   - Added check for applicable_countries field
   - Skip generic Ministerial/Final Approval for multi-layer workflows
   - Lines modified: ~40 lines in `_build_regulatory_tasks()`

2. **`backend/config/task_ontology.yaml`**
   - Renamed: "NLM Submission..." → "ClinicalTrials.gov Registration (NCT#)"
   - Renamed: "IRB Continuing Review" → "IRB/EC Continuing Review"
   - Renamed: "Regulatory Affairs Submits Final CSR to FDA" → "Final CSR Submission to Regulatory Authority"
   - Added: `applicable_countries: ["US"]` to REG-011
   - Updated descriptions to mention multiple regulatory authorities

---

## Benefits for Clinical Trial Managers

### 1. Accurate Country Information
- **Before**: "What does IND/CTA mean for my Kenya trial?"
- **After**: Clear identification: EC → PPB → NACOSTI

### 2. Realistic Regulatory Understanding
- **Before**: Saw generic "Ministerial Approval" with no context
- **After**: Sees exact 3-layer workflow with specific authority names

### 3. Applicable Tasks Only
- **Before**: Confused by FDA submission tasks in Kenya template
- **After**: Only sees tasks applicable to Kenya trials

### 4. Generic Tasks Stay Generic
- **Before**: "ClinicalTrials.gov Registration - Kenya" (wrong, it's not Kenya-specific)
- **After**: "ClinicalTrials.gov Registration (NCT#)" (correct, applies to all countries)

### 5. Country-Specific Planning
- Can identify country-specific bottlenecks (Kenya's 3-layer vs US parallel)
- Can plan realistic timelines based on actual authorities
- Can communicate with sponsors about specific approval requirements

---

## How It Works: Country-Specific Logic

### Template Generation Process

1. **Load Country Workflow**
   - Identifies workflow type (three_layer_sequential for Kenya)
   - Gets authority details (PPB, NACOSTI)

2. **Build Country-Specific Regulatory Tasks**
   - Creates REG-KE-EC, REG-KE-REG, REG-KE-NACOSTI
   - Uses actual authority names from regulatory_workflows.yaml
   - Appends "- Kenya" to make country-specific

3. **Build Ontology Regulatory Tasks**
   - Filters out US-only tasks (REG-001, REG-011)
   - Filters out tasks for other countries
   - Skips generic tasks when country has specific workflow
   - Uses task names as-is (NO country suffix)

4. **Build Operational Tasks**
   - All 92 ontology tasks (Site, Data, Closeout, etc.)
   - No country suffix (these are process tasks, not regulatory)

5. **Build Industry-Standard Milestones**
   - Protocol Development, Data Entry, Data Cleaning, etc.
   - No country suffix (these are universal milestones)

6. **Build Dependencies**
   - Links country-specific regulatory to operational
   - Links operational to closeout
   - Creates complete lifecycle chain

---

## Next Steps for Enhanced Country-Specificity

### Priority 1 (Based on Regulatory Authorities.txt):

1. **Add Country-Specific Fees**
   - Kenya PPB: $1,000 USD application fee
   - Kenya NACOSTI: Varies by applicant type (student, institution, commercial)

2. **Add Country-Specific Requirements**
   - Kenya: Dual CT registration (PPB + Pan African registry)
   - Kenya: County-level notifications in some cases
   - Kenya: EC must be NACOSTI-accredited (3-year terms)

3. **Add Country-Specific Timelines**
   - Kenya PPB: 30 working days (not calendar days)
   - Kenya NACOSTI: 1-year license validity
   - Kenya: Annual renewal required 6 weeks before expiration

### Priority 2:

4. **Add Special Circumstances**
   - Kenya fast-track procedures for public health emergencies
   - Kenya expedited review criteria

5. **Add Contact Information**
   - Kenya PPB: cta@pharmacyboardkenya.org
   - Kenya NACOSTI: customercare@nacosti.go.ke

---

## Validation Against Source Document

### Regulatory Authorities.txt Accuracy Check:

✅ **Correct**: "Pharmacy and Poisons Board" (not just "PPB")
✅ **Correct**: "National Commission for Science, Technology and Innovation" (full name, not just "NACOSTI")
✅ **Correct**: "Institutional Ethics Committee (EC)" (clarifies it's institutional, not national)
✅ **Correct**: Sequential workflow (EC → PPB → NACOSTI, not parallel)
✅ **Correct**: 30 working days for PPB review
✅ **Correct**: NACOSTI issues research licenses (separate from PPB drug approval)

---

## Deployment Status

✅ **Deployed to Render**: https://ilanapm.onrender.com
✅ **GitHub**: https://github.com/dmerrimon/ilanapm
✅ **Tested**: Kenya Phase III template verified
✅ **Verified**: US template still shows US-specific tasks correctly

---

## Conclusion

Templates are now **country-specific** with accurate regulatory authority names. Clinical Trial Managers can now see:

- **Kenya**: EC → PPB → NACOSTI (3-layer sequential)
- **Vietnam**: CEBRGL → ASTT → NECBR → Minister (4-layer sequential)
- **US**: FDA || IRB (parallel)
- **UK**: MHRA || REC (parallel integrated)

Generic tasks (ClinicalTrials.gov, IRB/EC Continuing Review, Protocol Amendments) remain generic across all countries.

---

*Implementation completed: January 22, 2026*
*Source: Regulatory Authorities.txt (Kenya section lines 16211-16410)*
